Payment overview · 2025
General Payments
$50.23
3 reported records · 3 companies
Healthcare provider profile · identity verified
Beth Ann Casady, DO FAAFP
Allopathic & Osteopathic Physicians|Family Medicine · SPRING CITY, TN · NPI 1720096159
Verified facts
What the public records show
CMS Open Payments records show Beth Ann Casady, DO FAAFP received $50.23 in general payments during 2025 across 3 reported records.
ABBVIE INC. accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.63 | 37.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.92 | 35.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.68 | 27.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $50.23 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 446 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 385 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 324 | 77 |
| Alprazolam | Alprazolam | 309 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 279 | 80 |
| Omeprazole | Omeprazole | 245 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 235 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 53 |
| Losartan Potassium | Losartan Potassium | 185 | 55 |
| Lisinopril | Lisinopril | 184 | 47 |
| Gabapentin | Gabapentin | 176 | 41 |
| Metformin Hcl | Metformin Hcl | 171 | 38 |
| Simvastatin | Simvastatin | 156 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 41 |
| Meloxicam | Meloxicam | 114 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 36 |
| Eliquis | Apixaban | 104 | 21 |
| Famotidine | Famotidine | 104 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 26 |
| Tramadol Hcl | Tramadol Hcl | 103 | 17 |
| Baclofen | Baclofen | 97 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 26 |
| Lorazepam | Lorazepam | 92 | 12 |
| Carvedilol | Carvedilol | 91 | 26 |
| Clonazepam | Clonazepam | 87 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 28 |
| Sertraline Hcl | Sertraline Hcl | 79 | 20 |
| Montelukast Sodium | Montelukast Sodium | 78 | 20 |
| Furosemide | Furosemide | 76 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 19 |
| Trazodone Hcl | Trazodone Hcl | 72 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 16 |
| Jardiance | Empagliflozin | 71 | 11 |
| Potassium Chloride | Potassium Chloride | 69 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 67 | 18 |
| Prednisone | Prednisone | 64 | 39 |
| Cefuroxime | Cefuroxime Axetil | 60 | 51 |
| Spironolactone | Spironolactone | 60 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | suppressed |
| Allopurinol | Allopurinol | 56 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 52 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 51 | 11 |
| Temazepam | Temazepam | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | 14 |
| Celecoxib | Celecoxib | 47 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 13 |
| Propranolol Hcl | Propranolol Hcl | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 39 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 24 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Atenolol | Atenolol | 39 | 13 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 11 |
| Sucralfate | Sucralfate | 36 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 33 | 11 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 11 |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $50.23 · 3 records | ABBVIE INC. | MOUNJARO, VRAYLAR, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error